Tryptamine Therapeutics (ASX:TYP) EBIT per Share : A$-0.02 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics EBIT per Share?

Tryptamine Therapeutics's EBIT per Share for the six months ended in Dec. 2023 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 13.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Tryptamine Therapeutics's EBIT per Share or its related term are showing as below:

ASX:TYP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -28.9 Med: -7.75 Max: 13.4
Current: 13.4

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Tryptamine Therapeutics was 13.40% per year. The lowest was -28.90% per year. And the median was -7.75% per year.

ASX:TYP's 3-Year EBIT Growth Rate is ranked better than
63.37% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs ASX:TYP: 13.40

Tryptamine Therapeutics's EBIT for the six months ended in Dec. 2023 was A$-1.93 Mil.

Tryptamine Therapeutics EBIT per Share Historical Data

The historical data trend for Tryptamine Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics EBIT per Share Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT per Share

Get a 7-Day Free Trial

-0.09

-0.19

-0.21

-0.14

-0.09

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial						-0.11	-0.03	-0.09	-	-0.01

Tryptamine Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Tryptamine Therapeutics's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.799	/	78.757
=	-0.09

Tryptamine Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.925	/	174.118
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02

Tryptamine Therapeutics (ASX:TYP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Tryptamine Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines